Sandra Kurtin - Concepedia

Author

Sandra Kurtin

Also Known As

Kurtin, Sandra, S E Kurtin, S Kurtin, S. Kurtin, Sandra E Kurtin, Sandra E. Kurtin, Sandra E. Kurtin, PhD, ANP-C, AOCN, Sandra E. Kurtin, PhD, ANP-C, AOCN, FAPO, Sandra E. Kurtin, PhDc, ANP-C, AOCN, Sandra E. Kurtin, RN, MS, AOCN, ANP-C

132

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

University of Arizona Arizona Oncology University of Arizona Cancer Center Moffitt Cancer Center Cleveland Clinic

About

Sandra Kurtin is an author at University of Arizona specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	678
2	Health Sciences	3	3	94
3	Nursing	3	3	48
4	Public Health	2	2	59
5	Allied Health Professions	1	1	10

Sandra Kurtin

Publications

798

Citations

H-Index

Page 1

	Year	Citations
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group Mario E. Lacouture, Michael L. Maitland, Siegfried Segaert, Supportive Care in Cancer MedicineToxicity Study GroupPathologyClinical DermatologyWound Healing	2010	148
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer Tomislav Dragovich, David S. Mendelson, Sandra Kurtin, Cancer Chemotherapy and Pharmacology MedicineColorectal CancerPathologyCancer TreatmentPhase 2	2006	137
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors Daruka Mahadevan, Ruth Plummer, Matthew Squires, Annals of Oncology Pharmacodynamic StudyOncologyMedicinePharmacotherapyRefractory Solid Tumors	2011	86
Myeloid Toxicity of Cancer Treatment Sandra Kurtin Journal of the Advanced Practitioner in Oncology Hematological MalignancyOncologyBone Marrow FailureMedicineMalignant Blood Disorder	2012	59
The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab–Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center Mohanad Al‐Obaidi, Ahmet B. Gungor, Sandra Kurtin, The American Journal of Medicine VaccinationPreventive MedicineLarge Academic CenterReal-world ExperienceTreatment And Prevention	2022	47
Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. Pavani Chalasani, Sandra Kurtin, Tomislav Dragovich PubMed	2008	43
Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents Sandra Kurtin, MSN Elizabeth Bilotti Journal of the Advanced Practitioner in Oncology Proteasome InhibitorsImmunologyPathologyPharmacotherapyImmunotherapy	2013	27
Caregivers of Multiple Myeloma Survivors Sandra Kurtin, K Lilleby, Jacy Spong Clinical journal of oncology nursing Multiple Myeloma SurvivorsCell Replacement TherapyTransplantation EligibilityMyeloid NeoplasiaHematological Malignancy	2013	26
Durable Long-Term Responses in Patients with Myelodysplastic Syndromes Treated with Lenalidomide Sandra Kurtin, Alan F. List Clinical Lymphoma & Myeloma Hematological MalignancyBone Marrow FailureHematologyDurable Long-term ResponsesMedicine	2009	21
The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail Christopher R. Cogle, Sandra Kurtin, Tanya G. K. Bentley, The Oncologist	2017	21

Page 1